articleJournal of NeuroscienceOct 15, 2003BRONZE OA

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

Beth Israel Deaconess Medical Center · Harvard University · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

The precise cause of neuronal death in Huntington's disease (HD) is unknown. Although no single specific protein-protein interaction of mutant huntingtin has emerged as the pathologic trigger, transcriptional dysfunction may contribute to the neurodegeneration observed in HD. Pharmacological treatment using the histone deacetylase inhibitor sodium butyrate to modulate transcription significantly extended survival in a dose-dependent manner, improved body weight and motor performance, and delayed the neuropathological sequelae in the R6/2 transgenic mouse model of HD. Sodium butyrate also increased histone and Specificity protein-1 acetylation and protected against 3-nitropropionic acid neurotoxicity.…

Citation impact

688
total citations
FWCI
13.03
Percentile
100%
References
72
Citations per year

Authors

11

Topics & keywords

Keywords
  • Sodium butyrate
  • Histone deacetylase
  • Phenotype
  • Huntington's disease
  • Cancer research
  • Histone deacetylase inhibitor
  • HDAC11
  • Medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.